B cells in the pathophysiology of autoimmune neurological disorders: a credible therapeutic target
- PMID: 16644016
- DOI: 10.1016/j.pharmthera.2006.03.005
B cells in the pathophysiology of autoimmune neurological disorders: a credible therapeutic target
Abstract
There is evidence that B cells are involved in the pathophysiology of many neurological diseases, either in a causative or contributory role, via production of autoantibodies, cytokine secretion, or by acting as antigen-presenting cells leading to T cell activation. Clonal expansion of B cells either in situ or intrathecally and circulating autoantibodies are critical elements in multiple sclerosis (MS), Devic's disease, paraneoplastic central nervous system disorders, stiff-person syndrome, myasthenia gravis, autoimmune demyelinating neuropathies and dermatomyositis. The pathogenic role of B cells and autoantibodies in central and peripheral nervous system disorders, as reviewed here, provides a rationale for investigating whether depletion of B cells with new agents can improve clinical symptomatology and, potentially, restore immune function. Preliminary results from several clinical studies and case reports suggest that B cell depletion may become a viable alternative approach to the treatment of autoimmune neurological disorders.
Similar articles
-
B cells as therapeutic targets in autoimmune neurological disorders.Nat Clin Pract Neurol. 2008 Oct;4(10):557-67. doi: 10.1038/ncpneuro0901. Epub 2008 Sep 23. Nat Clin Pract Neurol. 2008. PMID: 18813230 Review.
-
B cells move to centre stage: novel opportunities for autoimmune disease treatment.Nat Rev Drug Discov. 2006 Jul;5(7):564-76. doi: 10.1038/nrd2085. Nat Rev Drug Discov. 2006. PMID: 16816838 Review.
-
Neuroimmunology I: Immunoregulation in neurological disease.Ann Neurol. 1982 May;11(5):437-49. doi: 10.1002/ana.410110502. Ann Neurol. 1982. PMID: 6179458
-
Invited article: inhibition of B cell functions: implications for neurology.Neurology. 2008 Jun 3;70(23):2252-60. doi: 10.1212/01.wnl.0000313840.27060.bf. Neurology. 2008. PMID: 18519875 Review.
-
The role of pathogenic B-cell clones in antibody mediated autoimmune disorders.J Dermatol Sci. 2004 Dec;36(3):141-8. doi: 10.1016/j.jdermsci.2004.07.004. J Dermatol Sci. 2004. PMID: 15541635 Review.
Cited by
-
B cells as a target of immune modulation.Ann Indian Acad Neurol. 2009 Oct;12(4):221-5. doi: 10.4103/0972-2327.58275. Ann Indian Acad Neurol. 2009. PMID: 20182568 Free PMC article.
-
Advances in the immunobiology and treatment of inflammatory myopathies.Curr Rheumatol Rep. 2007 Aug;9(4):291-7. doi: 10.1007/s11926-007-0047-5. Curr Rheumatol Rep. 2007. PMID: 17688838 Review.
-
The preventive Effectiveness of Rituximab in Pediatric Autoimmune and Inflammatory CNS Diseases Relapse: an Iranian Experience.Iran J Child Neurol. 2022 Summer;16(3):167-182. doi: 10.22037/ijcn.v16i3.29322. Epub 2022 Jul 16. Iran J Child Neurol. 2022. PMID: 36204433 Free PMC article.
-
Successful treatment of paraneoplastic cerebellar degeneration with Rituximab.J Neurooncol. 2008 Feb;86(3):363-4. doi: 10.1007/s11060-007-9479-z. Epub 2007 Oct 9. J Neurooncol. 2008. PMID: 17924058 No abstract available.
-
Influence of fingolimod on basic lymphocyte subsets frequencies in the peripheral blood of multiple sclerosis patients - preliminary study.Cent Eur J Immunol. 2015;40(3):354-9. doi: 10.5114/ceji.2015.54599. Epub 2015 Oct 15. Cent Eur J Immunol. 2015. PMID: 26648781 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical